



**2019 Eligible Measure Applicability (EMA) for  
Merit-based Incentive Payment System (MIPS) Clinical  
Quality Measures (CQMs) Collection Type of Individual  
Measures**

5/13/2019

# 2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS CQMS COLLECTION TYPE

## MIPS Clinically Related Measure Analysis Used in EMA

### Clinical Relation including an Outcome/High Priority Test of the 2019 MIPS CQMs Collection Type

Note: MIPS CQMs that do not have any eligible instances for a clinically related measure should be submitted as 0/0. The analysis of the data would account for this when evaluating the score as it is related to EMA. Qualified vendors do not need to submit anything else to CMS for this scenario as the vendors attest that data they submit has been validated and is true, accurate, and complete to the best of their knowledge. If the vendor is selected for auditing, this may be one of the items audited to determine that the data submitted was true, accurate and complete.

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
1	Diabetes Mellitus Foot Care	126	N/A	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation
		127	N/A	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
2	Chronic Obstructive Pulmonary Disease (COPD) Care	51	N/A	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
		52	N/A	Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy
		130	N/A /High Priority	Documentation of Current Medications in the Medical Record
<i>Note: When submitting #130, they are not subject to EMA for these clinically related measures. If quality measures #51 and/or #52 are submitted, it is expected to submit quality measure #130.</i>				
3	Asthma Care	110	N/A	Preventive Care and Screening: Influenza Immunization
		130	N/A / High Priority	Documentation of Current Medications in the Medical Record
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		398	Outcome / High Priority	Optimal Asthma Control
		444	N/A / High Priority	Medication Management for People with Asthma
		474	N/A	Zoster (Shingles) Vaccination
<i>Note: When submitting #110, #130 or #226, they are not subject to EMA for these clinically related measures. If #398 and/or #444 are submitted, it is expected to submit quality measures 110, #130 and #226.</i>				
4	Hematology Care	67	N/A	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

**2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS  
CQMS COLLECTION TYPE**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
		68	N/A	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
		69	N/A	Hematology: Multiple Myeloma: Treatment with Bisphosphonates
		70	N/A	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
5	Melanoma Care	137	N/A / High Priority	Melanoma: Continuity of Care-Recall System
		138	N/A / High Priority	Melanoma: Coordination of Care
6	Osteoporosis Care	24	N/A / High Priority	Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older
		130	N/A / High Priority	Documentation of Current Medications in the Medical Record
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		418	N/A	Osteoporosis Management in Women Who Had a Fracture
<p><b>Note:</b> When submitting #130 or #226, they are not subject to EMA for these clinically related measures. It is expected to submit these quality measures if #24 and/or #418 are submitted. There is no requirement to submit both #24 and #418.</p>				
7	Appropriate Test/Treatment for Children	65	N/A / High Priority	Appropriate Treatment for Children with Upper Respiratory Infection (URI)
		66	N/A / High Priority	Appropriate Testing for Children with Pharyngitis
8	Acute Otitis Externa	91	N/A / High Priority	Acute Otitis Externa (AOE): Topical Therapy
		93	N/A / High Priority	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use
9	Adult Sinusitis Care	331	N/A / High Priority	Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)
		332	N/A / High Priority	Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)

**2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS  
CQMS COLLECTION TYPE**

<b>Number</b>	<b>Title</b>	<b>Quality ID</b>	<b>Outcome/High Priority</b>	<b>Quality Measure Title</b>
		<b>333</b>	N/A / High Priority	Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)
<b>10</b>	<b>Primary Open-Angle Glaucoma</b>	<b>12</b>	N/A	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
		<b>141</b>	Outcome / High Priority	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
<b>11</b>	<b>Cataract Care</b>	<b>191</b>	Outcome / High Priority	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
		<b>192</b>	Outcome / High Priority	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
		<b>303</b>	Patient Reported Outcome / High Priority	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
		<b>304</b>	Outcome / High Priority	Cataracts: Patient Satisfaction within 90 Days following Cataract Surgery
		<b>388</b>	Outcome / High Priority	Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy)
		<b>389</b>	Outcome / High Priority	Cataract Surgery: Difference Between Planned and Final Refraction
<b>12</b>	<b>Adult Renal Catheter Care</b>	<b>329</b>	Outcome / High Priority	Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis
		<b>330</b>	Outcome / High Priority	Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days
<b>13</b>	<b>Perioperative Care</b>	<b>21</b>	N/A / High Priority	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
		<b>23</b>	N/A / High Priority	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
<b>14</b>	<b>Coronary Artery Bypass Graft Care</b>	<b>165</b>	Outcome / High Priority	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate
		<b>166</b>	Outcome / High Priority	Coronary Artery Bypass Graft (CABG): Stroke
		<b>167</b>	Outcome / High Priority	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure
		<b>168</b>	Outcome / High Priority	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration

**2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS  
CQMS COLLECTION TYPE**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title		
		445	Outcome / High Priority	Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)		
15	Endoscopy and Polyp Surveillance	185	N/A / High Priority	Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use		
		320	N/A / High Priority	Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients		
		439	N/A / High Priority	Age Appropriate Screening Colonoscopy		
16	Urinary Incontinence Care	48	N/A	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older		
		50	N/A / High Priority	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older		
17	Coronary Disease Care	6	N/A	Coronary Artery Disease (CAD): Antiplatelet Therapy		
		7	N/A	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)		
		118	N/A	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)		
		130	N/A / High Priority	Documentation of Current Medications in the Medical Record		
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention		
		<b>Note:</b> When submitting #130 or #226 they are not subject to EMA for these clinically related measures. If quality measures #6, #7, and/or #118 are submitted, it is expected to submit quality measures #130 and #226.				
		18	Heart Failure Care	5	N/A	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
8	N/A			Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)		
130	N/A / High Priority			Documentation of Current Medications in the Medical Record		

**2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS  
CQMS COLLECTION TYPE**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
<i>Note: When submitting #130, it is not subject to EMA for these clinically related measures. If #5 and/or #8 are submitted, it is expected to submit quality measure #130.</i>				
19	Cardiac Stress Imaging	322	N/A / High Priority	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk-Surgery Patients
		323	N/A / High Priority	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)
		324	N/A / High Priority	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients
20	Breast Surgery Care	262	N/A / High Priority	Image Confirmation of Successful Excision of Image-Localized Breast Lesion
		264	N/A	Sentinel Lymph Node Biopsy for Invasive Breast Cancer
21	Retinal Care	384	Outcome / High Priority	Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery
		385	Outcome / High Priority	Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery
22	Heart Rhythm Care	348	Outcome / High Priority	HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate
		392	Outcome / High Priority	HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation
		393	Outcome / High Priority	HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision
23	Pathology Lung Cancer	395	N/A / High Priority	Lung Cancer Reporting (Biopsy/Cytology Specimens)
		396	N/A / High Priority	Lung Cancer Reporting (Resection Specimens)
24	Colonoscopy Care	130	N/A / High Priority	Documentation of Current Medications in the Medical Record
		425	N/A	Photodocumentation of Cecal Intubation
<i>Note: When submitting #130, it is not subject to EMA for these clinically related measures. If quality measure #425 is submitted, it is expected to submit #130.</i>				
25	Gynecological Care	422	N/A / High Priority	Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury
		432	Outcome / High Priority	Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair

**2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS  
CQMS COLLECTION TYPE**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
		433	Outcome / High Priority	Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair
		434	Outcome / High Priority	Proportion of Patients Sustaining A Ureter Injury at the Time of any Pelvic Organ Prolapse Repair
26	Headache Care	419	N/A / High Priority	Overuse of Imaging for the Evaluation of Primary Headache
		435	Patient Reported Outcome / High Priority	Quality of Life Assessment For Patients With Primary Headache Disorders
27	Anesthesiology Care	424	Outcome / High Priority	Perioperative Temperature Management
		430	N/A / High Priority	Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy
28	Opioid Care	408	N/A / High Priority	Opioid Therapy Follow-up Evaluation
		412	N/A / High Priority	Documentation of Signed Opioid Treatment Agreement
		414	N/A / High Priority	Evaluation or Interview for Risk of Opioid Misuse
		468	N/A / High Priority	Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)
29	Palliative Care	47	N/A / High Priority	Advanced Care Plan
		134	N/A	Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		342	Outcome / High Priority	Pain Brought Under Control Within 48 Hours
<p><b>Note:</b> When submitting #47 and/or #134, they are not subject to EMA for these clinically related measures. If #342 is submitted, it is expected to submit quality measures #47 and #134.</p>				
30	Preventive Care	112	N/A	Breast Cancer Screening
		113	N/A	Colorectal Cancer Screening
		130	N/A / High Priority	Documentation of Current Medications in the Medical Record
		317	N/A	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
<p><b>Note:</b> When submitting #130 or #317 they are not subject to EMA for these clinically related measures. It is expected to submit these quality measures if #112 and/or #113 are submitted. There is no requirement to submit both #112 and #113.</p>				
31	Immunization Care	110	N/A	Preventive Care and Screening: Influenza Immunization
		111	N/A	Pneumococcal Vaccination Status for Older Adults



**2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS  
CQMS COLLECTION TYPE**

<b>Number</b>	<b>Title</b>	<b>Quality ID</b>	<b>Outcome/High Priority</b>	<b>Quality Measure Title</b>
		<b>474</b>	N/A	Zoster (Shingles) Vaccination
<b>32</b>	<b>Parkinson's Disease</b>	<b>290</b>	N/A	Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease
		<b>291</b>	N/A	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment
		<b>293</b>	N/A / High Priority	Parkinson's Disease: Rehabilitative Therapy Options
<b>33</b>	<b>Cancer End of Life</b>	<b>453</b>	N/A / High Priority	Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score – better)
		<b>454</b>	Outcome / High Priority	Percentage of Patients who Died from Cancer with More than One Emergency Department Visit in the Last 30 Days of Life (lower score – better)
		<b>455</b>	Outcome / High Priority	Percentage of Patients Who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score – better)
		<b>456</b>	N/A / High Priority	Percentage of Patients Who Died from Cancer Not Admitted To Hospice lower score – better)
<b>34</b>	<b>Optimizing Patient Exposure to Ionizing Radiation</b>	<b>360</b>	N/A / High Priority	Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies
		<b>361</b>	N/A / High Priority	Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry
<b>35</b>	<b>Total Knee Replacement</b>	<b>350</b>	N/A / High Priority	Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy
		<b>351</b>	N/A / High Priority	Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation
		<b>352</b>	N/A / High Priority	Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet
		<b>353</b>	N/A / High Priority	Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report



**2019 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR MIPS  
CQMS COLLECTION TYPE**

<b>Number</b>	<b>Title</b>	<b>Quality ID</b>	<b>Outcome/High Priority</b>	<b>Quality Measure Title</b>
		<b>470</b>	Patient Reported Outcome / High Priority	Average Change In Functional Status Following Total Knee Replacement Surgery
<b>36</b>	<b>Inflammatory Bowel Disease</b>	<b>271</b>	N/A	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment
		<b>275</b>	N/A	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy
<b>37</b>	<b>Dementia</b>	<b>282</b>	N/A	Dementia: Functional Status Assessment
		<b>283</b>	N/A	Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management
		<b>286</b>	N/A / High Priority	Dementia: Safety Concerns Screening and Follow-Up for Patients with Dementia
		<b>288</b>	N/A / High Priority	Dementia: Education and Support of Caregivers for Patients with Dementia
<b>38</b>	<b>Lumbar Fusion</b>	<b>460</b>	Patient Reported Outcome / High Priority	Average Change in Back Pain Following Lumbar Fusion
		<b>469</b>	Patient Reported Outcome / High Priority	Average Change in Functional Status Following Lumbar Fusion Surgery
		<b>473</b>	Patient Reported Outcome / High Priority	Average Change in Leg Pain Following Lumbar Fusion Surgery